Special Issue

New Horizons in the Fight Against Vector-Borne Diseases and Parasitic Infestations: From Basic Research to Applied Studies in Vaccines

Message from the Guest Editors

Vaccines are among the most effective tools for preventing infectious diseases and have significantly reduced global mortality and morbidity. Advances in vaccine development and distribution over recent decades have enabled the control of several illnesses. reinforcing their strategic role in public health. Recent approvals of vaccines for dengue and malaria mark important progress. Yet, issues around efficacy, longterm safety, and large-scale implementation remain. To address these gaps, sustained investment in scientific research, innovation, and equitable access policies is essential. This Special Issue welcomes original articles. abstracts, and reviews that explore advanced concepts related to vaccine efficacy, safety, and costeffectiveness. Submissions that deepen our understanding of these aspects will support the development of more targeted, effective, and evidencebased public health strategies, particularly in regions most affected by vector-borne diseases. Dr. Maykelin Fuentes Zaldívar

Guest Editors

Dr. Rodolfo Cordeiro Giunchetti

Laboratório de Biologia das Interações Celulares, Departamento de Morfologia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil

Dr. Maykelin Fuentes Zaldivar

Laboratory of Biology of Cellular Interactions, Department of Morphology, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil

Deadline for manuscript submissions

30 April 2026



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/240306

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

